Atreca Announces Appointment of Dr. Stacey Ma and Stephen R. Brady to its Board of Directors
SAN CARLOS Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Dr. Stacey Ma, Executive Vice President and Head of Technical Operations at Sana Biotechnology, and Stephen R. Brady, Chief Executive Officer of Tempest Therapeutics, to its Board of Directors.
"We are pleased to be expanding our Board of Directors with the addition of two experienced and accomplished biopharmaceutical executives” said John Orwin, Chief Executive Officer. "Together, Stacey and Steve bring over 40 years of industry experience across a variety of corporate functions, including research, technical operations, manufacturing, corporate development and finance. Their expertise will be invaluable to Atreca as we continue to advance ATRC-101 and build our preclinical pipeline.”
Dr. Stacey Ma
Stephen R. Brady
About Atreca, Inc.
Source: Atreca, Inc.